MDMA References

1. Nichols, D.E., Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs, 1986. 18(4): p. 305-13.

2. Nichols, D.E. and R. Oberlender, Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann N Y Acad Sci, 1990. 600: p. 613-23; discussion 623-5.

3. Mithoefer, M.C., et al., The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol, 2011. 25(4): p. 439-52.

4. Mithoefer, M.C., et al., Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol, 2013. 27(1): p. 28-39.

5. Oehen, P., et al., A randomized, controlled pilot study of MDMA (± 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol, 2013. 27(1): p. 40-52.

6. Mithoefer, M.C., C.S. Grob, and T.D. Brewerton, Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry, 2016. 3(5): p. 481-8.